



MILAN
CHAMBER OF
ARBITRATION

LIFE SCIENCES WARS: ARBITRATION STRIKES BACK

Milan, 27 November 2025

MEET THE SPEAKERS!





MILAN
CHAMBER OF
ARBITRATION



Martina Lucenti

Partner, Portolano Cavallo, Italy

**Chair of the 16th
CAM Annual Conference**

Martina Lucenti is a partner at Portolano Cavallo. Martina focuses on domestic and international litigation and arbitration. She assists Italian and foreign clients in commercial and corporate disputes, post-M&A litigation, directors' and officers' liability suits. She also assists companies in civil actions for vicarious liability brought before criminal courts.

Martina has gained broad industry experience in Life Sciences & Healthcare litigation, representing pharmaceutical and biotechnological companies, medical devices manufacturers, hospitals and clinics in disputes arising out of R&D, manufacturing, license, supply, marketing and distribution agreements and in product liability cases. She regularly serves as sole, co-arbitrator, and presiding arbitrator in proceedings administered by the Milan Chamber of Arbitration and ad hoc arbitration. She is recognized by the Lexology Index in the rankings Arbitration Future Leaders – Partners 2025 and Italy – Arbitration 2025, where she is listed as “Recommended”.



MILAN
CHAMBER OF
ARBITRATION



Andrea Ferrari

Sandoz, Chief Integrity Officer &
Global Head Corporate Legal, Italy

PANEL 1

Why Life Sciences businesses are increasingly looking to arbitration to resolve disputes

Andrea Ferrari is Global Head of Corporate Legal and Chief Integrity Officer at Sandoz.

With over 20 years of experience in the pharmaceutical and life sciences sector, he has a strong track record in M&A, licensing, and complex cross-border contracting.

He played a leading role in the Sandoz spin-off and listing on the SIX Swiss Exchange, and previously served as Head of Legal M&A at Takeda, driving major integrations such as Takeda–Shire.

Before moving in-house, Andrea worked at Freshfields Bruckhaus Deringer and Goldman Sachs in London and Milan.

Recognized in Legal 500's GC Powerlist, he is a regular speaker on legal, compliance, and corporate governance matters.



MILAN
CHAMBER OF
ARBITRATION



Henry Stewart

Partner, Cooley, UK

PANEL 1

Why Life Sciences businesses are increasingly looking to arbitration to resolve disputes

Henry is a partner on Cooley's commercial disputes team in London and serves on Cooley's global life sciences advisory board. He advises clients on a wide range of commercial issues requiring resolution through investigations, litigation, arbitration or other dispute resolution processes, with a particular focus on the life sciences and technology sectors.

Throughout his career, Henry has acted in several high-value, international arbitrations and regularly leads on some of Cooley's most sensitive and high-profile disputes.

He also has extensive experience assisting governments and companies in the investigation and recovery of assets lost to fraud and corruption, consistently achieving positive outcomes for clients through the courts, arbitration and other tailored resolution methods.



MILAN
CHAMBER OF
ARBITRATION



Janine Reudt-Demont

Partner, Niederer Kraft Frey,
Switzerland

PANEL 2

*The moving boundaries of
arbitrability in the Life Sciences
sector: is there any room for ADR in
product liability and IP disputes?*

Janine Reudt-Demont works as Partner for the full-service law firm Niederer Kraft Frey (NKF) in Zurich where she co-leads the firm's Life Sciences & Healthcare practice. Her experience covers the regulation of all aspects of the medtech and pharmaceutical industries. Janine also advises clients on distribution, product liability and product safety laws, including product recalls, and is regularly involved in industry-related mediations, arbitrations and state court proceedings.

Next to her over 10 years of experience as a lawyer in a large law firm, she also gained valuable industry insights when she was seconded to build up a pharma company's compliance department.

Janine regularly speaks on and publishes in her areas of expertise, in particular as co-editor of the Life Science Recht Journal.



MILAN
CHAMBER OF
ARBITRATION



Simon Dack

Barrister, Member of PMAC of the
Unified Patent Court Expert
Committee, Netherlands

PANEL 2

*The moving boundaries of
arbitrability in the Life Sciences
sector: is there any room for ADR in
product liability and IP disputes?*

Simon Dack (b. 1965) began his career in 1987 as a patent examiner at the EPO in Munich before qualifying as a European patent attorney and later being called to the English bar in 1999.

He worked as a barrister and Dutch advocaat at De Brauw Blackstone Westbroek, becoming partner in 2005, and in 2010 co-founded Hoyng ROKH Monegier, a leading European patent litigation boutique. His practice focused on major disputes in pharmaceuticals, biotechnology, and medical devices.

Alongside litigation, he taught IP law at Leiden University (2018–2021) and has long contributed to *Tekst & Commentaar*. Since 2023, after 36 years in patents (23 in litigation), he has focused on trial advisory work, mock trials for UPC litigants, and drafting the framework for the Patent Arbitration and Mediation Centre (PMAC) of the UPC, expected to open in 2026.



MILAN
CHAMBER OF
ARBITRATION



Stefano De Donno

Managing Director,
MicroPort Scientific, Italy

FOCUS

Medical Device Industry in Italy. Risk management and challenges ahead

Stefano De Donno is Managing Director at MicroPort Scientific srl. With over 20 years of progressive experience in the medical devices industry, combining deep financial expertise with strong commercial leadership, holds extensive international experience across EMEA, Asia, and LATAM, covering Sales Operations and commercial business development.

His background includes M&A and IPO activities, as well as auditing and risk management with a specific focus on compliance and business ethics. A strategic and results-oriented leader, recognized for developing and guiding cross-functional teams, extensive experience in assessing, mitigating, and monitoring corporate risks, with a proven ability to implement effective risk management strategies that safeguard business continuity and support the achievement of organizational objectives. He is member of the Board of Statutory Auditors of Confindustria Dispositivi Medici the industry association of MD.



MILAN
CHAMBER OF
ARBITRATION



Conna Weiner

International Mediator and
Arbitrator, JAMS / Conna Weiner
ADR, USA

PANEL 3

*Navigating Life Sciences
disputes. An arbitrator's
perspective*

Conna Weiner is a full time international arbitrator and mediator with a unique background in litigation, transactions, IP and broad in-house experience in the U.S. and internationally, including as a General Counsel. She specializes in complex commercial, life sciences, transactional, health care, technology and intellectual property disputes.

She has served as sole arbitrator, party-appointed arbitrator, and tribunal chair in cases administered by many of the leading providers such as ICC, ICDR, JAMS, CPR, ad hoc matters and others, and is known for combining legal expertise with practical business insight. Her deep industry knowledge helps parties design effective processes and reach sustainable solutions. She is a Fellow of the Chartered Institute of Arbitrators, a Fellow of the College of Commercial Arbitrators and was named among the World's Leading Technology Neutrals by the Silicon Valley Arbitration and Mediation Center.



MILAN
CHAMBER OF
ARBITRATION



Gregory K Bell

Gregory K Bell - Group Vice President and Life Sciences Practice Leader, Charles River Associates, USA

PANEL 3
Navigating Life Sciences disputes. An arbitrator's perspective

Gregory K Bell, MBA, PhD, leads the global Life Sciences consulting practice at Charles River Associates (CRA).

As an expert witness, Dr. Bell frequently testifies on quantum in intellectual property, finance, valuation, transfer pricing and antitrust litigation in courts and arbitration proceedings in North America, Europe, Asia, and Australia.

He brings accounting, business, economics, and finance expertise to his expert witness engagements.

With three decades of experience as a strategy consultant in life sciences, Dr Bell has a comprehensive knowledge of global markets and therapeutic categories to inform his expert opinions in disputes associated with the pharmaceutical, biotechnology, medical devices, diagnostics, and wellness industries.



MILAN
CHAMBER OF
ARBITRATION

**SEE YOU IN MILAN ON
27 NOVEMBER!**

May the clause be with you!

